



2nd Annual Jefferson Liver Disease Symposium

Saturday, April 2, 2016

Learning Objectives

At the conclusion of this CME activity, participants will be able to:

- Identify and appraise the new and emerging innovative drug treatments for the management of chronic hepatitis C infection in special populations, e.g. ESRD patients.
- Debate the possibility of achieving a cure in patients with chronic hepatitis B infection receiving anti-viral therapies.
- Integrate an evidence-based approach to the management of patients with hepatocellular carcinoma (HCC) to determine the best therapy from surgical, loco-regional and systemic chemotherapeutic options.
- Review an evidence-based approach to diagnosing and managing patients with DILI.
- Discuss the key aspects of diagnosing and managing acute liver failure.
- Review the advancements made in the non-invasive assessment of liver fibrosis with techniques such as Fibroscan and MR elastography and assess their role in clinical care.
- Describe the role of the transplant hepatologist and describe recent changes in the fellowship training pathway and ABIM-accreditation process.
- Review surgical updates in the evolving field of liver transplantation.
- Discuss and analyze the novel approaches to treating patients with nonalcoholic fatty liver disease (NAFLD).
- Identify the systemic complications of cirrhosis including a diagnostic and therapeutic approach to acute kidney injury, varices and hepatic encephalopathy and adopt strategies to integrate evidence based guidelines into practice.
- Assess their individual practice in light of the information and discussions during the course, and identify specific strategies to implement as part of a continuing improvement process for their practices.